HomeInsightsMarket Capitalization

Market Capitalization of Epigral Ltd

Market Capitalization of Epigral Ltd

stocks purchased

₹ 0.7 Cr

Volume Transacted

(Dec 11, 2024)

stocks purchased

3.4 K

Stocks Traded

(Dec 11, 2024)

Last Updated on: Dec 11, 2024

Image

Epigral Ltd

NSE: EPIGRAL

Market Cap

₹ 9288.33 crore

Last updated on: Dec 10, 2024

Key Highlights

  • The Market Cap of Epigral Ltd is ₹ 9288 crore as of 10 Dec 24 .
  • The Market Cap of Epigral Ltd changed from ₹ 4045 crore on March 2022 to ₹ 4553 crore on March 2024 . This represents a CAGR of 4.02% over 3 years.
  • The Latest Trading Price of Epigral Ltd is ₹ 2145 as of 11 Dec 16:00 .
  • The Dividend Payouts of Epigral Ltd changed from ₹ 2.5 on Feb 01, 2023 to ₹ 5 on Jul 02, 2024 . This represents a CAGR of 25.99% over 3 years.

Historical Market Cap of Epigral Ltd

No data available

* All values are in crore

Company Fundamentals for Epigral Ltd

No data available

Image

Epigral Ltd

NSE: EPIGRAL

Share Price

₹ 2145.55

-7.45 (-0.35%)

stock direction

Last updated on: Dec 11, 2024

Market Price of Epigral Ltd

1M

1Y

3Y

5Y

Monitoring Epigral Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Market Price

Date
leftPrice (₹)right
10 Dec 20242153
09 Dec 20242118.95
06 Dec 20242090.2
05 Dec 20242126.35
04 Dec 20242126.5
03 Dec 20242095.9
02 Dec 20242064.3
29 Nov 20242076.55
28 Nov 20242074.5
27 Nov 20241993.05

SWOT Analysis Of Epigral Ltd

Strength

6

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Epigral Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

Asset Value vs Market Value of Epigral Ltd

Market Value

0

Asset Value

0

* All values are in Rupees

Competitive Comparison of Market Cap

Key Valuation Metric of Epigral Ltd

No data available

No data available

Historical P/E Ratio of Epigral Ltd

No data available

* All values are in %

Historical Revenue of Epigral Ltd

No data available

* All values are in crore

Historical EBITDA of Epigral Ltd

No data available

* All values are in crore

Historical Net Profit of Epigral Ltd

No data available

* All values are in crore

Historical Dividend Payouts of Epigral Ltd

No data available

* All values are in

About Epigral Ltd

  • Epigral Limited was erstwhile incorporated as Meghmani Finechem Limited in 2007, which engaged in manufacturing and selling of Chlor Alkali & its Derivatives and also in Trading of Agrochemical products.
  • The Company was incorporated as a subsidiary of Meghmani Organics Limited. Meghmani Finechem Limited (MFL) was demerged from Meghmani Organics Limited (MOL) as a going concern through the Scheme of Arrangement for Demerger and the said Scheme became effective from May 10, 2021.
  • The Chlor-Alkali business commissioned in 2009, growing from an installed capacity of 1,88,000 TPA in 2015 to 3,15,000 TPA at the close of FY 2020-21.
  • The Company is now among the leading players in India's chlor alkali industry.
  • In terms of the said Scheme, the Company allotted 2,39,03,029 Equity Shares of Rs 10/- each on 20th May, 2021 to the shareholders of Meghmani Organics Limited.

Epigral Ltd News Hub

News

Board of Epigral approves doubling of capacity at Dahej

The Board of Epigral at its meeting held on 09 November 2024 has approved the expansion of...

Read more

09 Nov 2024 13:31

News

Epigral to table results

Epigral will hold a meeting of the Board of Directors of the Company on 9 November 2024 Po...

Read more

30 Oct 2024 16:17

News

Epigral allots 15.19 lakh equity shares under QIP issue

Epigral has allotted 15,19,180 equity shares at an issue price of Rs 2093.13 per equity sh...

Read more

25 Oct 2024 11:57

News

Board of Epigral approves fund raising up to Rs 500 cr

The Board of Epigral at its meeting held on 14 August 2024 has approved fund raising up to...

Read more

14 Aug 2024 15:22

News

Epigral to convene board meeting

Epigral will hold a meeting of the Board of Directors of the Company on 14 August 2024. Po...

Read more

10 Aug 2024 11:11

News

Board of Epigral to consider proposal for fund raising

The Board of Epigral will meet on 14 August 2024 to consider proposal for raising of funds...

Read more

09 Aug 2024 17:18

Product Composition

Document

Annual Reports

N/A

dropdown
download

Credit Ratings

N/A

dropdown
download

Concalls

Data not available

FAQs for Epigral Ltd Market Cap

What is the market cap of Epigral Ltd?

As of December 11, 2024, Epigral Ltd has a market capitalization of ₹9288.33, however, this figure is subject to change due to fluctuations in its stock price and market conditions.

What factors influence Epigral Ltd's market capitalization?

Epigral Ltd's market capitalization is influenced by factors such as its financial performance, and the company’s ability to innovate and adapt to market trends. Moreover, macroeconomic factors like economic conditions, currency fluctuations, and global automotive industry trends also affect its market capitalization.

Can market capitalization be used to predict future stock performance of Epigral Ltd?

Market capitalization alone is not a reliable predictor of future stock performance, as it reflects the current value of a company's equity rather than its future potential. To forecast %s's future stock performance, investors should consider additional factors such as financial health, growth prospects, industry trends, and broader economic conditions.

How often does Epigral Ltd's market capitalization change?

Epigral Ltd's market capitalization can change frequently, within a single trading day, due to fluctuations in stock price. These changes are influenced by market conditions, investor sentiment, company performance, and broader economic factors. Therefore, tracking its market capitalization requires continuous monitoring of stock price movements and related financial news.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Demat Account
Verify your phone
+91
*By signing up you agree to our terms & conditions